Attached files
| file | filename |
|---|---|
| 8-K - 8-K - INTUITIVE SURGICAL INC | a8-kq413preliminaryearning.htm |
| EX-99.1 - EX-99.1 - INTUITIVE SURGICAL INC | ex-991q4prerelease.htm |
Exhibit 99.2
Intuitive Surgical, Inc Unaudited Preliminary Q413 and FY13 Revenue Data and Metrics | |||||||||||||||||
Q413 | Q412 | Change | FY13 | FY12 | Change | ||||||||||||
Revenue ($Millions) | |||||||||||||||||
Instruments and Accessories | $ | 268.2 | $ | 253.8 | 6 | % | $ | 1,032.9 | $ | 903.3 | 14 | % | |||||
Systems | 204.6 | 264.9 | (23 | )% | 834.9 | 932.9 | (11 | )% | |||||||||
Services | 103.4 | 90.6 | 14 | % | 397.3 | 342.6 | 16 | % | |||||||||
Total Revenue | $ | 576.2 | $ | 609.3 | (5 | )% | $ | 2,265.1 | $ | 2,178.8 | 4 | % | |||||
System Unit Sales by Geography | |||||||||||||||||
United States | 72 | 133 | (46 | )% | 342 | 476 | (28 | )% | |||||||||
Europe | 28 | 24 | 17 | % | 82 | 64 | 28 | % | |||||||||
Japan | 21 | 10 | 110 | % | 79 | 40 | 98 | % | |||||||||
Other Markets | 17 | 8 | 113 | % | 43 | 40 | 8 | % | |||||||||
Total Systems | 138 | 175 | (21 | )% | 546 | 620 | (12 | )% | |||||||||
System Unit Sales by Product | |||||||||||||||||
da Vinci S | — | 8 | (100 | )% | 6 | 40 | (85 | )% | |||||||||
Si Single Console | 79 | 122 | (35 | )% | 365 | 449 | (19 | )% | |||||||||
Si Dual Console | 38 | 32 | 19 | % | 145 | 105 | 38 | % | |||||||||
Sie | 21 | 13 | 62 | % | 30 | 26 | 15 | % | |||||||||
Total Systems | 138 | 175 | (21 | )% | 546 | 620 | (12 | )% | |||||||||
Other Metrics | |||||||||||||||||
System Average Selling Price ($Millions) | $ | 1.46 | $ | 1.49 | (2 | )% | $ | 1.52 | $ | 1.49 | 2 | % | |||||
Inst & Accy Revenue/Procedure ($Thousands) | $ | 1.93 | $ | 2.05 | (6 | )% | $ | 1.98 | $ | 2.01 | (1 | )% | |||||
System Trade-In's | 44 | 52 | (15 | )% | 155 | 167 | (7 | )% | |||||||||
System Installed Base | 2,965 | 2,585 | 15 | % | 2,965 | 2,585 | 15 | % | |||||||||
Page 1 of 2
Intuitive Surgical, Inc. Unaudited Preliminary Trended Annual Procedure Data | |||||||||||
Approximate Procedures (Thousands) | Percentage Change | ||||||||||
2011 | 2012 | 2013 | 2012 | 2013 | |||||||
United States | |||||||||||
Gynecology | 170 | 222 | 240 | 31 | % | 8 | % | ||||
Urology | 93 | 88 | 85 | (5 | )% | (3 | )% | ||||
General Surgery | 15 | 42 | 81 | 180 | % | 93 | % | ||||
Other | 14 | 15 | 16 | 7 | % | 7 | % | ||||
Total United Sates | 292 | 367 | 422 | 26 | % | 15 | % | ||||
Total International | 68 | 83 | 101 | 22 | % | 22 | % | ||||
Total Worldwide | 360 | 450 | 523 | 25 | % | 16 | % | ||||
The 2013 U.S. gynecology procedure growth rate was lower than in previous years, reflecting a number of factors including, but not limited to, apparent pressure on benign gynecology hospital admissions, negative media reports, and a trend by payers toward encouraging conservative disease management and treatment methods in outpatient settings. Lower 2013 U.S. urology volume was driven by the full year impact in 2013 of decreasing da Vinci prostatectomy (dVP) volumes in 2012, reflecting the U.S. Preventive Services Task Force recommendation against prostate-specific antigen (“PSA”) screening, as well as changes in treatment pattern for low risk prostate cancer away from definitive treatment. U.S. dVP volumes appear to have stabilized throughout 2013. International procedure growth was driven primarily by higher dVP procedure volume.
# # #
This report contains forward-looking statements. Such statements relate to preliminary unaudited trended annual procedure data, preliminary unaudited Q4 and full year 2013 revenue data and metrics, and other related subjects. The preliminary unaudited results are prior to the completion of review and audit procedures and are therefore subject to adjustment. These forward-looking statements are based on Intuitive Surgical’s current plans and expectations and are subject to risks and uncertainties that could cause actual events and results to vary significantly from those implied by such statements. Please refer to Intuitive Surgical’s reports and filings with the SEC for a further discussion of these risks and uncertainties.
Page 2 of 2